LALeonor Mendonça Almeida

Leonor Mendonça Almeida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leonor Mendonça Almeida has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • A. Magalhães

    Pulmonology Department, Centro Hospitalar de São João, Porto, Portugal

    1 shared publication
  • A. Morais

    Pulmonology Department, Centro Hospitalar de São João, Porto, Portugal; Faculdade de Medicina da Universidade do Porto, Porto, Portugal

    1 shared publication
  • Adelina Amorim

    Pulmonology Department of ULS São João, Cystic Fibrosis Reference Center, ULS São João, Rua de Miguel Bombarda 234, 4050-377, Porto, Portugal; Faculty of Medicine, University of Porto (FMUP), Rua de Miguel Bombarda 234, 4050-377, Porto, Portugal

    1 shared publication
  • Ana Luisa Pereira

    Pharmaceutical Service, ULS São João, Rua de Miguel Bombarda 234, 4050-377, Porto, Portugal

    1 shared publication
  • Ana Luísa Fernandes

    Pulmonology Department, Hospital Pedro Hispano, Matosinhos, Portugal

    1 shared publication
  • Anabela Marinho

    Pulmonology department, Centro Hospitalar e Universitário São João, Porto, Portugal

    1 shared publication

Latest Publications

  • N1303K (p.Asn1303Lys) variant: Expanding frontiers in the treatment of cystic fibrosis

    by Joana Pacheco, Leonor Almeida, Rita Boaventura, Ana Luisa Pereira, Claudia S. Rodrigues, Violeta Railean, Iris Al. Silva, Ines Pankonien, Margarida D. Amaral, Adelina Amorim


  • Open Access

    Mortality risk prediction with ILD-GAP index in a fibrotic hypersensitivity pneumonitis cohort

    by Leonor Mendonça Almeida, Ana Luísa Fernandes, Catarina Gouveia Cardoso, Bruno Lima, Inês Neves, Hélder Novais-Bastos, Patrícia Caetano Mota, Natália Melo, Conceição Souto Moura, Susana Guimarães, et al.

    Background: Fibrotic hypersensitivity pneumonitis (fHP) is associated with significant morbidity and mortality. Interstitial lung disease–gender-age-physiology (ILD-GAP) performance in fHP outside the initial cohort was never performed. Aim: To assess the ILD-GAP index’s ability to predict mortality in a Portuguese cohort of patients with fHP and analyse whether other clinical variables add value. Methods: Retrospective analysis of fHP cohort in two Portuguese ILD centres. The baseline ILD-GAP index was calculated. Survival was analysed in months; mortality was the primary outcome. Univariate and multivariate analyses to identify mortality risk factors were performed. Results: A total of 141 patients were included. Fifty-three patients (37.6%) died during the follow-up. The usual interstitial pneumonia (UIP) pattern was found in 49.6%, and their survival was inferior to non-UIP [32 months (interquartile range, IQR = 19, 60) versus 52 months (IQR = 28, 98), p = 0.048]. Patients with an ILD-GAP index higher than three double their risk of mortality [hazard ratio (HR) = 6.48, 95% confidence interval (CI) = (3.03–13.96)] when compared with the patients with an index between 2 and 3 [HR = 3.04, 95% CI = (1.62–5.71)] adjusting for acute exacerbation history. Even though UIP patients had worse survival, it did not reach statistical significance when UIP pattern was added to this model. Acute exacerbation history was an independent risk factor for mortality; however, ILD-GAP still predicted mortality after adjusting for this factor. PaO2 and 6-minute walk test desaturation were not significant risk factors. Conclusion: ILD-GAP index is a good predictor for mortality in fHP, even after adjusting for other mortality risk factors.


  • Open Access

    Non-invasive ventilation in the elderly – never too late!

    by Leonor Mendonça Almeida, Maria Jacob, Mafalda Van Zeller, Tiago Pinto, Miguel Gonçalves, Marta Drummond

    Dear Editor, Practising evidence-based medicine in an ageing population is challenging. Nevertheless, using age as a diagnostic or therapeutic procedure contraindication is less and less common. Domiciliary non-invasive ventilation (NIV) in chronic respiratory failure patients has been largely used; however, data from older people is scarce...

  • Massive Pulmonary Thrombosis Following Haemoptysis in Type IV Ehlers–Danlos Syndrome

    by Leonor Mendonça Almeida, Célia Sousa, Paulo Vilares Morgado, Pedro Fernandes, José Amado, José Artur Paiva, Anabela Marinho, João Paulo Oliveira


  • Non-invasive ventilation in the very old – what to expect?

    by Leonor Furtado Almeida Cunha, Maria Jacob, Mafalda Van Zeller, Tiago Pinto, Miguel Gonçalves, Marta Drummond

    Introduction: Evidence-based medicine in aging population is challenging. Nevertheless, using age as an contraindication is less and less common. Non-invasive ventilation (NIV) in the chronic setting has been largely used, however data from older people is scarce. Methods: Retrospective analysis of NIV adapted patients with ≥75 years old in one year in a chronic setting. Evaluation of efficacy and adhesion at 12 months. Results: The were 261 in-lab adaptations to NIV and 82 (31.4%) performed in patients older than 75 were included. The majority were male (43|52.4%), mean age of 82.1±5 years old. Indications to treatment were: Obstructive Sleep Apnoea with hypoventilation (23|28%), COPD (17|20.7%) and Obesity-hypoventilation syndrome (16|19.5%). Most patients (72%) presented with hypercapnic respiratory failure and were adapted to NIV in spontaneous-temporized mode (91.5%) with mean IPAP of 19.2±4.4 mmHg and EPAP of 7.47±2.4 mmHg. Adhesion at 12 months was 83.9% with 7:28h/night. Twenty-eight (34%) suspended NIV during follow-up. In this group of patients, there was a significant reduction in PaCO2 at 30 days (51±10.5 mmHg vs 44.6±6.9 mmHg, p<0.001) and at 12 months (42.3±7.0mmHg, p<0.001). A reduction in hospitalizations for respiratory failure was also observed (1.02 vs 0.29/year, p<0.001). Sixteen patients died in the first year (19.5%). When two age groups - <85 and ≥85 – were compared, there were no significant differences between groups in none of the analysed variables. Conclusion: NIV is an effective treatment even in very old patients, correcting hypercapnia and reducing hospitalization, reinforcing that age shouldn’t be an exclusion criterion for this therapeutic option.

  • Open Access

    Learning curve for transbronchial lung cryobiopsy in diffuse lung disease

    by L.M. Almeida, B. Lima, P.C. Mota, N. Melo, A. Magalhães, J.M. Pereira, C.S. Moura, S. Guimarães, A. Morais

    Transbronchial lung cryobiopsy (TBLC) is increasingly used in the diagnosis of diffuse lung disease (DLD), but no data have yet been published on the learning curve associated with this technique. To evaluate diagnostic yield, lung tissue sample length and area, and procedure-related complications in a cohort of TBLC procedures to define the learning curve and threshold for proficiency. Retrospective analysis of the first 100 TBLCs performed in different segments of the same lobe in patients with suspected DLD. We compared diagnostic yield, sample length and area, and complications between consecutive groups of patients. The overall diagnostic yield for TBLC was 82%. Median sample length was 5.4mm (IQR, 5-6) and median area was 19.5mm2 (IQR, 13.3-25). Pneumothorax was the most common complication (18%). On comparing the two groups of 50 consecutive patients, a significant difference was found for diagnostic yield (74% vs 90%; p=0.04), sample length (5.0mm [2.5-16] vs 6.0mm [4-12;] p<0.01) and area (17.5mm2 [6-42] vs 21.5mm2 [10-49]; p<0.01). Logarithm regression was applied to median diagnostic yield and sample length and area for groups of 10 consecutive patients to define the learning curve, which plateaued after approximately 70 procedures. Our findings suggest that proficiency in TBLC is achieved at approximately the 70th procedure; however they need to be validated in more series and cohorts.